Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy
Biomerica, Inc. (BMRA)
NASDAQ:AMEX Investor Relations:
biomerica.com/company/investor.asp
Company Research
Source: GlobeNewswire
Key Highlights Responder Analysis: 59.4% of patients achieved =30% reduction in abdominal pain; 68.1% achieved =30% reduction in bloating—using the FDA-recognized responder endpoint consistent with the Company’s peer-reviewed randomized controlled trial.CMS Payment Rate: $300 national Medicare payment rate established, effective January 1, 2026.Physician Perspective: New interview with Gastroenterologist Dr. Dak Patel about inFoods IBS in clinical use now available at https://investors.biomerica.com/events-and-presentations/default.aspx IRVINE, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), an innovator in diagnostic-guided therapy, today announced responder analysis results from its ongoing real-world study of inFoods® IBS. The data demonstrates that a majority of patients achieved clinically meaningful reductions in both abdominal pain and bloating—the two most debilitating symptoms of Irritable Bowel Syndrome (IBS). Responder Analysis
Show less
Read more
Impact Snapshot
Event Time:
BMRA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BMRA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BMRA alerts
High impacting Biomerica, Inc. news events
Weekly update
A roundup of the hottest topics
BMRA
News
- Biomerica Reports Real-World Data: Nearly 60% of IBS Patients Achieved Clinically Meaningful Pain Reduction and 68% Achieved Bloating Reduction with the inFoods® IBS Therapy [Yahoo! Finance]Yahoo! Finance
- Vietnam Approves Biomerica’s EZ Detect™ for Nationwide DistributionGlobeNewswire
- Biomerica Reports Second Quarter Fiscal 2026 Financial ResultsGlobeNewswire
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS Test [Yahoo! Finance]Yahoo! Finance
- Biomerica Announces CMS Medicare Payment Rate of $300 for Revolutionary inFoods® IBS TestGlobeNewswire
BMRA
Sec Filings
- 2/27/26 - Form S-8
- 1/28/26 - Form 4
- 1/14/26 - Form 10-Q
- BMRA's page on the SEC website